Related Experiment Video
Updated: Aug 1, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
[CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification)--a long-term follow-up study]
M Okamoto1, F Maruyama, M Tsuzuki
1Dept. of Medicine Fujita Health University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1994
Summary
The CAMBO-VIP chemotherapy regimen achieved high complete remission rates in advanced diffuse large cell lymphoma patients. This treatment demonstrated good tolerability and long-term survival, making it effective for this cancer.
Area of Science:
- Oncology
- Hematology
- Clinical Pharmacology
Background:
- Diffuse large cell lymphoma is an aggressive non-Hodgkin lymphoma.
- Advanced stages often require intensive treatment regimens.
- Evaluating novel chemotherapy combinations is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the efficacy and tolerability of the CAMBO-VIP chemotherapy regimen.
- To determine remission rates, survival, and adverse events in patients with advanced diffuse large cell lymphoma.
Main Methods:
- A cohort of 22 patients with advanced diffuse large cell lymphoma (LSG classification) was treated.
- The treatment regimen included cyclophosphamide, doxorubicin, methotrexate with leucovorin rescue, bleomycin, vincristine, etoposide, ifosfamide, and prednisolone (CAMBO-VIP).
- Data on remission, relapse, survival, and toxicity were collected and analyzed.
Main Results:
- Complete remission was achieved in 90% (18/20) of evaluable patients.
- At a median follow-up of 52 months, 3 patients relapsed (17%), and 2 patients died.
- Actuarial 4-year overall survival and relapse-free survival were estimated at 90% and 83%, respectively.
- The regimen was generally well-tolerated, with transient myelosuppression being the most significant side effect. No treatment-related fatalities occurred.
Conclusions:
- The CAMBO-VIP regimen is an effective and well-tolerated treatment for advanced diffuse large cell lymphoma.
- High remission and survival rates suggest its potential as a valuable therapeutic option.
- Further studies may explore its role in comparison to other treatment modalities.
